Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 131
Filtrar
3.
J Thorac Cardiovasc Surg ; 166(3): 837-838, 2023 09.
Artigo em Inglês | MEDLINE | ID: mdl-35219515
7.
Circulation ; 146(6): e50-e68, 2022 08 09.
Artigo em Inglês | MEDLINE | ID: mdl-35862152

RESUMO

The use of temporary mechanical circulatory support in cardiogenic shock has increased dramatically despite a lack of randomized controlled trials or evidence guiding clinical decision-making. Recommendations from professional societies on temporary mechanical circulatory support escalation and de-escalation are limited. This scientific statement provides pragmatic suggestions on temporary mechanical circulatory support device selection, escalation, and weaning strategies in patients with common cardiogenic shock causes such as acute decompensated heart failure and acute myocardial infarction. The goal of this scientific statement is to serve as a resource for clinicians making temporary mechanical circulatory support management decisions and to propose standardized approaches for their use until more robust randomized clinical data are available.


Assuntos
Oxigenação por Membrana Extracorpórea , Insuficiência Cardíaca , Coração Auxiliar , American Heart Association , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/terapia , Coração Auxiliar/efeitos adversos , Humanos , Balão Intra-Aórtico/efeitos adversos , Choque Cardiogênico/diagnóstico , Choque Cardiogênico/etiologia , Choque Cardiogênico/terapia
8.
J Card Surg ; 37(3): 571-573, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34981862

RESUMO

One-year outcomes of Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET), a randomized double-blinded clinical trial comparing post-coronary artery bypass surgery antiplatelet therapy with ticagrelor versus aspirin are published in this issue of the Journal. Although the authors did not detect statistically significant differences in their primary outcome (saphenous vein graft patency at 1 year) and major adverse cardiovascular events, their findings must be interpreted with caution given important limitations in the design and execution of the trial.


Assuntos
Inibidores da Agregação Plaquetária , Veia Safena , Aspirina , Oclusão de Enxerto Vascular/prevenção & controle , Humanos , Resultado do Tratamento , Grau de Desobstrução Vascular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...